Bluebird bio, Inc.
BLUE
Hisse Senetlerindeki Sıralama
#15678
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Hisse Fiyatı
$4.97
Son senkronizasyon: 2025-06-02
Piyasa Değeri
$318.62M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-38.03%
Ülke
US
Ticaret Bluebird bio, Inc. (BLUE)
Kategori
Healthcare
Piyasa Değeri Bluebird bio, Inc.(BLUE)
Piyasa Değeri: $318.62M
October 2026 itibarıyla Bluebird bio, Inc. şirketinin piyasa değeri $318.62M. Bu, verilerimize göre Bluebird bio, Inc. şirketini dünyanın en değerli 15678th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
Bluebird bio, Inc. piyasa değeri geçmişi (2018 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında BLUE
